Baxdrostat plus dapagliflozin · Prevent-HF
AstraZeneca identifies Prevent-HF as ongoing development in its approval release. Existing hypertension approval and BaxHTN/Bax24 blood-pressure data do not answer this heart-failure/CV-death trial. baxdrostat — phase 3 study in Heart Failure. NCT06677060 measures To determine if baxdrostat/dapagliflozin is superior to placebo/dapagliflozin in reducing the risk of an HF event or CV death (Event driven; Up to 38 months). Registry status: recruiting.
What matters
Track what the company has actually announced, the study or asset involved, and the evidence needed to confirm the milestone.
- Specify the exact future analysis/cohort and verify that it remains unpublished before creating any tradeable question.
- Registry design and recruitment status are not evidence of efficacy or regulatory approval.
- An active study record does not establish that its primary outcome is still unannounced. Review sponsor disclosures before promotion to a future catalyst.
Primary evidence
Long-horizon HF study — date unconfirmed
Potential outcome market
Will baxdrostat meet the prespecified primary endpoint in NCT06677060 by a listing deadline still to be specified?
This event is research, not a listed market. A market needs a precise question, resolution rules and liquidity before trading opens.